Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.

ABSTRACT: Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to inhibit AR-mediated prostate cancer cell proliferation. Following the initial promising clinical efficacy results in phase I and II clinical trials of patients with metastatic castrate-resistant prostate cancer (CRPC), apalutamide has been investigated in several phase III trials. Particular interest has focused on the development of effective therapy for the prevention of disease progression in patients with nonmetastatic (nm or M0) CRPC, especially patients who have a rapid prostate-specific antigen (PSA) doubling time that is indicative of shorter bone metastasis-free survival and associated with significant morbidity and mortality. The results from the phase III SPARTAN trial were recen

SUBMITTER: Koshkin VS 

PROVIDER: S-EPMC6295778 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature